Super Spammer Board. The Best One on the YHOO Finance Website. Congratulations to all the excellent and tireless work by the ECA message board spammers. Kudos to TheStreet, CapitalCube, 24/7WallSt, and Zacks for their fine newsfeed spamming efforts too. The two groups - ECA message board spammers and ECA newsfeed spammers, are a marvelous collaborative effort indeed. You will all get a very nice bonus at the end of 2016 you turdballs.
----I just made a mistake of buying CREE shares and underestimating the level of hype built into CREE's share price.----
Wow so you finally admit you had (still have?) a position in CREE. I don't understand why you couldn't just respond directly to that simple question. Anyway, you have gained my respect for now.. You're no the only one that got caught up in the hype you know. It' happens every time a new technology appears. Some companies succeed other don't. CREE is a dog. AYI turned out to be the star. In retrospect, splitting the investment cross both companies would have been the way to play this sector. Too late now. I won't touch either. I've not gained or lost much over the years with CREE, but it was a massive waste of time and opportunity. You win some you lose some.
--save some powder for the Lumileds IPO--
Why? Do you think that company will do so much better than CREE? Conversely, do you think CREE is a good investment now? I follow the space, but I am not impressed with the returns. AYI seems to be the one company consistently profiting from the ongoing transition in lighting.
SHPG has a PDUFA ruling due July 22.
@Shire has received a new PDUFA date for its dry eye drug lifitegrast after the FDA accepted its resubmitted new drug application (NDA). The FDA assigned the drug a six-month review period, setting an action date of July 22, 2016. The FDA in October 2015 had decided against approving lifitegrast because it had failed to hit a major trial endpoint. After receiving the FDA's complete response letter, Shire resubmitted a new drug application (NDA) including data from five clinical trials. With the five clinical trials and 2,500 plus patients, Shire claims the lifitegrast trial program is the largest for an investigational-stage compound in dry eye disease. Shire's new phase 3 data includes positive outcomes from a 12-week, placebo-controlled trial where patients had statistically significant improvements in their dry eye disease symptoms. The resubmitted NDA includes this OPUS-3 trial data, along with product quality information Lifitegrast has a unique mode of action. It is an intercellular adhesion molecule (ICAM) inhibitor that modifies the immune functions that lead to dry eye. Shire has pegged lifitegrast as a likely blockbuster. Currently, Allergan's Restasis is the only approved treatment for dry eye disease, leaving the market ripe for a new entrant.
My point was you are probably underestimating what the SHPG share price will be after the deal closes. It has been held down by arbitrage players, and will likely surge when these players wind down their trade.
not once did jcreamer respond to my inquiries as to whether he holds a position in CREE. This message board is intended for CREE investors and traders. This guy does not appear to be either, and yet he has the nerve to question the motives of others who have disclosed this basic information.
If anyone should be flagged here it's you. You are harassing everyone on this board with endless unsubstantiated accusations.
All excellent questions. But I doubt CREE management would answer any of them if asked.
I don't see that happening until the FDA issues new rules to regulate (or ban) menthol cigarettes. I'm guessing this could take another year or two, but what do I know, I'm not a lawyer.
@March 02, 2016 WINSTON-SALEM, N.C. -- R.J. Reynolds Tobacco Co. has appealed a decision that would allow the U.S. Food and Drug Administration (FDA) to use a contested Tobacco Products Scientific Advisory Committee (TPSAC) report on menthol cigarettes. The TPSAC committee unanimously recommended the FDA ban the use of menthol in cigarettes. According to a report in the Winston-Salem Journal, the appeal comes after a Jan. 15, 2016, decision by a three-judge panel for the U.S. Court of Appeals for D.C. reversing a previous federal court judge ruling in favor of Reynolds and Lorillard Inc. Reynolds and Lorillard had argued the FDA allowed three advisory committee members to serve despite having conflicts of interest due to financial relationships with pharmaceutical tobacco-cessation-product manufacturers. If the FDA were to ban menthol, analysts project a potential surge in demand for smoking-cessation products due to the fact that 30% of all adult smokers use menthol products. Reynolds has a strong stake in the outcome of this case since the company’s June 2015 purchase of Lorillard and its top-selling Newport menthol brand. The deal cost Reynolds $29.25 billion and increased the manufacturer’s menthol-cigarette market share to 57%. Before the deal officially went through, Reynolds chief executive Susan Cameron said she believed the FDA would not attempt to enact severe restrictions on menthol cigarettes. But now there is less certainty on the matter.
You really need to sharpen that pencil you used to calculate this BXLT price target. It translates to a corresponding price of only 195 for SHPG.
NILSY is a beautiful cash cow.
@NORILSK NICKEL BOARD OF DIRECTORS RECOMMENDS FY2015 DIVIDEND OF RUB 230 PER SHARE Moscow, April 28, 2016 – The Board of Directors of MMC Norilsk Nickel (hereinafter ‘Norilsk Nickel’ or ‘the Company’ recommended for the AGM approval the dividend payment for the full financial year 2015 in the amount of RUB 230.14 (approximately USD 3.46 at the RUB/USD exchange rate of the Russian Central Bank as of 27.04.16) per one ordinary share. The total dividend distribution will amount to approximately USD 548 million. The Board of Directors has also proposed to set the dividend record date on June 21, 2016.
With lousy earnings and the adverse impact of new tax inversion rules on the TEX-Konecranes deal, management has to act quickly and decisively to strike a deal with Zoomlion. I am disappointed they did not make an announcement to that effect on the earnings call. It looks more and more like a no-brainer.